Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CARLOS E BUESO-RAMOS and ELIAS JOSEPH JABBOUR.
CARLOS E BUESO-RAMOS
Connection Strength
3.370
ELIAS JOSEPH JABBOUR
  1. Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive?B-ALL and pose a diagnostic challenge. Am J Hematol. 2024 04; 99(4):721-726.
    View in: PubMed
    Score: 0.236
  2. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
    View in: PubMed
    Score: 0.151
  3. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
    View in: PubMed
    Score: 0.150
  4. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
    View in: PubMed
    Score: 0.146
  5. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.142
  6. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.141
  7. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92.
    View in: PubMed
    Score: 0.140
  8. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 May; 38(5):1178-1181.
    View in: PubMed
    Score: 0.059
  9. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592.
    View in: PubMed
    Score: 0.057
  10. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. 2023 10; 98(10):E281-E284.
    View in: PubMed
    Score: 0.057
  11. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.054
  12. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.050
  13. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410.
    View in: PubMed
    Score: 0.050
  14. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771.
    View in: PubMed
    Score: 0.049
  15. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
    View in: PubMed
    Score: 0.049
  16. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.
    View in: PubMed
    Score: 0.049
  17. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.049
  18. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.049
  19. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
    View in: PubMed
    Score: 0.048
  20. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):338-344.
    View in: PubMed
    Score: 0.048
  21. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
    View in: PubMed
    Score: 0.047
  22. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.
    View in: PubMed
    Score: 0.047
  23. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
    View in: PubMed
    Score: 0.047
  24. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol. 2020 Oct; 105(4):449-459.
    View in: PubMed
    Score: 0.046
  25. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.045
  26. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.
    View in: PubMed
    Score: 0.045
  27. Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. Am J Hematol. 2019 09; 94(9):1049-1051.
    View in: PubMed
    Score: 0.042
  28. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.
    View in: PubMed
    Score: 0.042
  29. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
    View in: PubMed
    Score: 0.042
  30. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
    View in: PubMed
    Score: 0.041
  31. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
    View in: PubMed
    Score: 0.041
  32. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer. 2018 10 01; 124(19):3849-3855.
    View in: PubMed
    Score: 0.041
  33. Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget. 2018 09 28; 9(76):34449.
    View in: PubMed
    Score: 0.041
  34. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
    View in: PubMed
    Score: 0.041
  35. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.041
  36. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
    View in: PubMed
    Score: 0.040
  37. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
    View in: PubMed
    Score: 0.040
  38. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.039
  39. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
    View in: PubMed
    Score: 0.039
  40. Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget. 2018 Feb 16; 9(13):10987-10994.
    View in: PubMed
    Score: 0.039
  41. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.038
  42. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017 10; 102(10):1661-1670.
    View in: PubMed
    Score: 0.037
  43. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. Am J Hematol. 2017 08; 92(8):E168-E171.
    View in: PubMed
    Score: 0.037
  44. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
    View in: PubMed
    Score: 0.037
  45. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1405-1410.
    View in: PubMed
    Score: 0.037
  46. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
    View in: PubMed
    Score: 0.037
  47. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587.
    View in: PubMed
    Score: 0.037
  48. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
    View in: PubMed
    Score: 0.036
  49. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore). 2016 Oct; 95(41):e4934.
    View in: PubMed
    Score: 0.036
  50. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
    View in: PubMed
    Score: 0.034
  51. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol. 2016 Jun; 91(4):E274-6.
    View in: PubMed
    Score: 0.034
  52. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb; 91(2):227-32.
    View in: PubMed
    Score: 0.034
  53. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76.
    View in: PubMed
    Score: 0.032
  54. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34.
    View in: PubMed
    Score: 0.032
  55. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
    View in: PubMed
    Score: 0.031
  56. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16.
    View in: PubMed
    Score: 0.030
  57. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
    View in: PubMed
    Score: 0.029
  58. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.028
  59. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
    View in: PubMed
    Score: 0.028
  60. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70.
    View in: PubMed
    Score: 0.026
  61. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.
    View in: PubMed
    Score: 0.025
  62. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb 26; 113(9):1892-8.
    View in: PubMed
    Score: 0.021
  63. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
    View in: PubMed
    Score: 0.018
  64. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.